Material Event (Form 8-K)

Item 8.01 Other Items.

As previously disclosed, on August 19, 2025, Genprex, Inc. (the "Company") received a letter from the Listing Qualifications Staff (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with the minimum stockholders' equity requirement for the continued listing of the Company's common stock (the "Common Stock") on the Nasdaq Capital Market, under Listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement").

Also as previously disclosed, the Nasdaq Hearings Panel (the "Panel") of Nasdaq notified the Company on November 25, 2025, that the Panel had approved the Company's request for an exception until December 31, 2025, to demonstrate long-term compliance with the Stockholders' Equity Requirement.

As a result of proceeds raised from the Company's previously disclosed registered direct offerings which closed on October 24, 2025 and October 29, 2025, proceeds raised from the Company's usage of its "at the market" offering with H.C. Wainwright & Co., and the Company's usage of its equity line of credit with Lincoln Park Capital, LLC, as of the date of this Current Report on Form 8-K, the Company believes it has stockholders' equity in excess of the Stockholders' Equity Requirement. However, the Panel has not yet determined whether the Company has regained compliance with the Stockholders' Equity Requirement, and until the Panel determines that the Company is compliant with all applicable listing standards, there can be no assurance that the Common Stock will remain listed on the Nasdaq Capital Market.

Cautionary Language Concerning Forward-Looking Statements

This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to the Company's ability to regain (as applicable) and maintain compliance with the continued listing requirements of Nasdaq and maintain the listing of the Company's common stock; statements about the future listing of the Company's common stock; statements about the Company's intentions and plans for addressing Nasdaq listing deficiencies, including statements about plans for regaining compliance and intended actions following the Nasdaq Panel hearing and Panel decision; and statements about the Company's intentions and plans including anticipated actions and requests in connection with the Nasdaq process, requests for further extensions, statements about requested relief from Nasdaq or the hearing Panel or the type of relief that may be available; statements regarding plans that the Company may implement or actions that the Company may take in furtherance of regaining compliance; statements about the Company's financial results and ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines; and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which the Company operates and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or the Company's financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in "Risk Factors" in the Company's most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2024, the Company's Quarterly Reports on Form 10-Q filed since such Annual Report on Form 10-K, and the Company's other filings from time to time with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.